Cleveland Clinic Health System - East Region
Cleveland Clinic Health System - East Region was paid $40.67M by Medicaid between Jan 2018 and Dec 2024, across 282 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
EUCLID, OH 44119
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 102,423 | $2.86M | |
| 2019 | 93,203 | $2.91M | |
| 2020 | 68,724 | $4.00M | |
| 2021 | 96,341 | $5.57M | |
| 2022 | 92,203 | $5.03M | |
| 2023 | 281,622 | $12.43M | |
| 2024incomplete | 208,785 | $7.87M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 59,199 | 55,709 | $7.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 50,229 | 46,170 | $6.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 18,040 | 13,809 | $6.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 44,287 | 39,053 | $6.13M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.4% | 10,020 | 8,769 | $1.39M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 4,333 | 3,642 | $1.24M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 6,658 | 6,092 | $1.05M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 12,875 | 10,715 | $989K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 3,063 | 2,573 | $911K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 12,086 | 4,950 | $906K |
| G0378 | Hospital observation service, per hour | 2.0% | 13,807 | 6,111 | $813K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 4,286 | 3,990 | $539K |
270 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 3,691 | $510K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 2,086 | $420K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 3,173 | $408K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,309 | $389K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,060 | $386K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,263 | $348K |
| 80053 | Comprehensive metabolic panel | <1% | 53,980 | $294K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,248 | $272K |
| 87631 | <1% | 1,338 | $215K | |
| 81513 | <1% | 1,089 | $171K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 633 | $161K |
| 93975 | <1% | 986 | $128K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,962 | $110K |
| 70491 | <1% | 268 | $98K | |
| 70498 | <1% | 329 | $91K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,673 | $90K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,865 | $86K |
| 97161 | <1% | 2,508 | $83K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,851 | $71K |
| 12001 | <1% | 358 | $65K | |
| 10060 | <1% | 331 | $64K | |
| 93971 | <1% | 841 | $62K | |
| 71250 | <1% | 674 | $60K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,014 | $55K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 382 | $52K |
| 82805 | <1% | 1,352 | $48K | |
| 97116 | <1% | 1,953 | $48K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,744 | $47K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,119 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 544 | $45K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 53,179 | $43K |
| 97165 | <1% | 890 | $41K | |
| 84484 | <1% | 16,874 | $41K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 70,681 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,485 | $40K |
| 64493 | <1% | 108 | $39K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 295 | $39K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26,884 | $36K |
| 85027 | <1% | 16,012 | $35K | |
| 93970 | <1% | 238 | $35K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,500 | $34K |
| 72131 | <1% | 414 | $34K | |
| 86850 | <1% | 1,411 | $33K | |
| 76830 | Ultrasound, transvaginal | <1% | 690 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,138 | $33K |
| 97802 | <1% | 590 | $33K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 546 | $32K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,267 | $30K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 874 | $27K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 980 | $26K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 180 | $25K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 80 | $25K |
| 70486 | <1% | 632 | $24K | |
| 93799 | <1% | 4,988 | $24K | |
| 96127 | <1% | 296 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,240 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 616 | $23K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 52 | $22K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,019 | $21K |
| 80061 | Lipid panel | <1% | 1,744 | $20K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 908 | $18K |
| 86900 | <1% | 1,430 | $17K | |
| 82962 | <1% | 12,354 | $17K | |
| 81001 | <1% | 47,709 | $16K | |
| 96367 | <1% | 528 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,381 | $15K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 379 | $15K |
| 12011 | <1% | 78 | $15K | |
| 80069 | <1% | 1,401 | $14K | |
| 82728 | <1% | 1,202 | $14K | |
| 86780 | <1% | 1,741 | $14K | |
| 64483 | <1% | 42 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 30 | $13K |
| 99221 | <1% | 529 | $12K | |
| 70496 | <1% | 389 | $12K | |
| 85610 | <1% | 7,213 | $12K | |
| 83735 | <1% | 20,292 | $12K | |
| 84702 | <1% | 1,428 | $11K | |
| 90715 | <1% | 748 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,767 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 914 | $11K |
| 72100 | <1% | 1,012 | $10K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 949 | $9K |
| 73564 | <1% | 1,044 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,370 | $9K |
| 87340 | <1% | 509 | $9K | |
| 73030 | <1% | 1,102 | $9K | |
| 83540 | <1% | 1,303 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,019 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 227 | $8K |
| 83970 | <1% | 393 | $8K | |
| 82607 | <1% | 582 | $8K | |
| 76857 | <1% | 744 | $8K | |
| 73610 | <1% | 1,252 | $7K | |
| 76801 | <1% | 558 | $7K | |
| 86140 | <1% | 2,235 | $7K | |
| 96376 | <1% | 3,999 | $7K | |
| 83550 | <1% | 1,294 | $7K | |
| 73630 | <1% | 1,374 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 421 | $7K |
| 62323 | <1% | 14 | $6K | |
| 86803 | <1% | 320 | $6K | |
| 86901 | <1% | 1,430 | $6K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 370 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 794 | $6K |
| 73130 | <1% | 1,197 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,562 | $6K |
| 74018 | <1% | 474 | $6K | |
| 73502 | <1% | 775 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $6K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $6K |
| 84439 | <1% | 338 | $5K | |
| 83880 | <1% | 2,690 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,235 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 597 | $5K |
| 82570 | <1% | 505 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,900 | $5K |
| 12002 | <1% | 24 | $4K | |
| 74183 | <1% | 12 | $4K | |
| 36430 | <1% | 17 | $4K | |
| 97162 | <1% | 100 | $4K | |
| 93798 | <1% | 89 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,218 | $4K |
| 73560 | <1% | 627 | $4K | |
| 82077 | <1% | 3,691 | $3K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 22 | $3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17 | $3K |
| 97113 | <1% | 80 | $3K | |
| 99218 | <1% | 150 | $3K | |
| 80320 | <1% | 300 | $3K | |
| 84100 | <1% | 903 | $3K | |
| 82553 | <1% | 637 | $3K | |
| 73110 | <1% | 616 | $3K | |
| 83690 | <1% | 9,663 | $3K | |
| 82550 | <1% | 5,318 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 883 | $3K |
| A9270 | Non-covered item or service | <1% | 2,605 | $2K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 77 | $2K |
| 80076 | <1% | 233 | $2K | |
| 99224 | <1% | 277 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 844 | $2K |
| 76770 | <1% | 16 | $2K | |
| 87077 | <1% | 1,501 | $2K | |
| 97810 | <1% | 45 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 43 | $2K |
| 87430 | <1% | 2,039 | $1K | |
| 81025 | <1% | 28,075 | $1K | |
| 82043 | <1% | 206 | $1K | |
| 96368 | <1% | 80 | $1K | |
| 76536 | <1% | 14 | $1K | |
| 98927 | <1% | 36 | $1K | |
| 73590 | <1% | 385 | $1K | |
| 83605 | <1% | 2,753 | $1K | |
| 86703 | <1% | 1,217 | $1K | |
| 82330 | <1% | 1,478 | $1K | |
| 87481 | <1% | 992 | $1K | |
| 73140 | <1% | 223 | $1K | |
| 90686 | <1% | 47 | $1K | |
| 73700 | <1% | 14 | $1K | |
| 85730 | <1% | 1,184 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,749 | $897.84 |
| 84550 | <1% | 320 | $805.01 | |
| 87205 | <1% | 1,478 | $796.92 | |
| 83874 | <1% | 64 | $775.69 | |
| 85379 | <1% | 2,108 | $768.31 | |
| 87186 | <1% | 1,166 | $730.66 | |
| 99152 | <1% | 276 | $719.72 | |
| 85018 | <1% | 1,419 | $716.84 | |
| 71101 | <1% | 137 | $710.30 | |
| 80197 | <1% | 34 | $666.24 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,199 | $646.84 |
| 84132 | <1% | 1,627 | $637.48 | |
| 85652 | <1% | 191 | $602.97 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 71 | $601.33 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $585.92 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 126 | $540.46 |
| J1815 | Injection, insulin, per 5 units | <1% | 100 | $532.43 |
| 82435 | <1% | 1,237 | $516.17 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 452 | $503.13 |
| 64494 | <1% | 104 | $501.98 | |
| 82375 | <1% | 1,280 | $498.14 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,723 | $474.68 |
| 00731 | <1% | 99 | $447.26 | |
| 94760 | <1% | 2,194 | $436.53 | |
| 72040 | <1% | 38 | $426.44 | |
| 73080 | <1% | 226 | $395.10 | |
| 87070 | <1% | 278 | $364.57 | |
| 87808 | <1% | 1,057 | $359.55 | |
| 80177 | <1% | 117 | $349.90 | |
| 82010 | <1% | 742 | $308.88 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,336 | $307.08 |
| 84481 | <1% | 32 | $306.85 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $291.53 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 767 | $288.85 |
| 87040 | <1% | 814 | $288.74 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 944 | $286.28 |
| 99225 | <1% | 28 | $273.81 | |
| 84295 | <1% | 1,352 | $269.21 | |
| 97811 | <1% | 24 | $248.59 | |
| 76870 | <1% | 15 | $244.65 | |
| 73090 | <1% | 128 | $244.42 | |
| 84703 | <1% | 963 | $236.32 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 334 | $231.12 |
| 83050 | <1% | 991 | $208.70 | |
| 82150 | <1% | 282 | $208.19 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,157 | $197.21 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,425 | $145.85 |
| 86706 | <1% | 30 | $143.85 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,289 | $120.60 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 452 | $119.61 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 363 | $119.57 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 20 | $119.50 |
| 82272 | <1% | 95 | $116.51 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,618 | $112.19 |
| 82746 | <1% | 44 | $107.68 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,602 | $107.59 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,489 | $107.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,706 | $99.65 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,572 | $88.70 |
| 86308 | <1% | 158 | $82.19 | |
| 80164 | <1% | 13 | $79.13 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 320 | $76.62 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 370 | $75.68 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 625 | $68.24 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 117 | $66.35 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 180 | $63.45 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,217 | $59.64 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,795 | $53.08 |
| 72020 | <1% | 61 | $53.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,201 | $49.64 |
| 85045 | <1% | 45 | $46.97 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,792 | $42.01 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,088 | $40.47 |
| 82140 | <1% | 14 | $34.26 | |
| J3490 | Unclassified drugs | <1% | 21 | $25.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 864 | $19.98 |
| 87088 | <1% | 63 | $15.98 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 75 | $12.37 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26 | $8.37 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 47 | $4.18 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17 | $2.50 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 621 | $2.19 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 49 | $1.61 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 46 | $1.30 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 23 | $1.04 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 28 | $0.86 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 26 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 195 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 12 | $0.00 |
| 87529 | 0% | 33 | $0.00 | |
| 51798 | 0% | 19 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 72 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 32 | $0.00 |
| 3074F | 0% | 40 | $0.00 | |
| 73552 | 0% | 13 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 17 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 51 | $0.00 |
| 3078F | 0% | 224 | $0.00 | |
| 3077F | 0% | 30 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 540 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 14 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 39 | $0.00 |
| 80179 | 0% | 14 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 152 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 21 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 30 | $0.00 |
| 80143 | 0% | 15 | $0.00 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 12 | $0.00 |
| 64495 | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.